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Introduction
!
The role of small-bowel capsule endoscopy (SBCE)
in the evaluation of patients with known or sus-
pected Crohn’s disease is still evolving. The small
bowel is involved in approximately 80% of pa-
tients with Crohn’s disease, and in up to one-third
of cases the small bowel is the only segment of the
digestive tract affected by the disease [1]. More-
over, SBCE has consistently demonstrated the
highest diagnostic yield when compared with
other small-bowel imaging modalities for the de-
tection of mucosal lesions suggestive of Crohn’s
disease, particularly for mild lesions and those lo-
cated in the proximal small bowel [2,3]. SBCEmay
be useful to confirm or exclude the diagnosis in
patients with suspected Crohn’s disease, and it
may also be used to assess disease extent and ac-
tivity in patients with a previously established di-
agnosis of Crohn’s disease. However, endoscopic
findings are nonspecific and must be carefully
interpreted within the proper clinical context [4].
The availability of an objective and reproducible
measuring instrument, with good interobserver
agreement, seems essential for the assessment of
inflammatory activity and extent. Such an instru-
ment would also help to standardize the termi-
nology and method of interpretation of lesions
that are consistent with Crohn’s disease, and es-
tablish cutoff levels indicative of the severity of
inflammation. The classical threshold of more
than three ulcers to diagnose Crohn’s disease as
proposed by Mow et al. [5] has been widely used,
although it does not evaluate the size or distribu-
tion of the ulcers or account for other lesions typ-
ical of Crohn’s disease, such as villous edema or
stenoses. Moreover, it does not define cutoff lev-
els to classify inflammatory activity according to
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Background and study aims: The Lewis score was
developed to measure mucosal inflammatory ac-
tivity as detected by small-bowel capsule endos-
copy (SBCE). The aim of the current study was to
validate the Lewis score by assessing interobser-
ver correlation and level of agreement in a clinical
setting.
Patients and methods: This was a retrospective,
single-center, double-blind study including pa-
tients with isolated small-bowel Crohn’s disease
who underwent SBCE. The Lewis score was calcu-
lated using a software application, based on the
characteristics of villous edema, ulcers, and ste-
noses. The Lewis score was independently calcu-
lated by one of three investigators and by a central
reader (gold standard). Interobserver agreement
was assessed using intraclass correlation (ICC)
coefficient and Bland–Altman plots.
Results: A total of 70 patients were consecutively
included (mean age 33.9±11.7 years). The mean
Lewis score was 1265 and 1320 for investigators
and the central reader, respectively. There was a
high correlation, both for scores obtained for
each tertile (first tertile r=0.659–0.950, second
tertile r=0.756–0.906, third tertile r=0.750–
0.939), and for the global score (r=0.745–0.928)
(P<0.0001). Interobserver agreement was almost
perfect between the investigators and the central
reader (first tertile ICC=0.788–0.971, second ter-
tile ICC=0.824–0.943, third tertile ICC=0.857–
0.968, global score ICC=0.852–0.960; P<0.0001).
The inflammatory activity was classified as nor-
mal (score<135) in 2.9% vs. 2.9%, mild (score≥
135–<790) in 51.4% vs. 55.7%, and moderate to
severe (score≥790) in 45.8% vs. 41.4% of patients,
respectively (P<0.001).
Conclusion: A strong interobserver agreement
was demonstrated for the determination of the
Lewis score in a practical clinical setting, validat-
ing this score for the reporting of small-bowel in-
flammatory activity. The Lewis score might be
used for diagnosing, staging, follow-up, and ther-
apeutic assessment of patients with isolated
small-bowel Crohn’s disease. .
grade of severity, and it has been shown to yield a positive predic-
tive value for the diagnosis of Crohn’s disease of only 50%–69%
[6].
The recently introduced quantitative scoring systems such as the
Lewis score [7] and the capsule endoscopy Crohn’s disease activ-
ity index (CECDAI or Niv Score) [8] have overcome some of these
limitations. The CECDAI has been validated recently in a multi-
center prospective study [9], whereas the Lewis score has not
yet undergone such validation. Nevertheless, the Lewis score, a
cumulative scoring system based on the characteristics and dis-
tribution of villous edema, ulceration, and stenosis, has been con-
verted into a user-friendly software application, which calculates
the score automatically. With this application, the small bowel is
automatically divided into equal thirds (tertiles) based on the
transit time of the capsule. For each tertile, a numeric subscore
(based on the extent and distribution of edema, and the number,
size, and distribution of ulcers) is calculated. The final score is cal-
culated by adding the score for the worst-affected tertile to the
score for stenosis (single/multiple, ulcerated/not ulcerated, tra-
versed/not traversed by the capsule):
Lewis score=
inflammatory score of the worst-affected tertile [(villous param-
eter×extent×descriptor)+(ulcer number×extent×size)]+steno-
sis score (number×ulcerated×traversed).
The Lewis score classifies small-bowel inflammatory activity into
three grades of severity of inflammation: 1) normal or clinically
insignificant mucosal inflammatory change (score<135); 2) mild
disease (score≥135–<790); and 3) moderate-to-severe disease
(score≥790). Although widely used, this score has not yet been
externally validated for use in clinical practice.
The aim of this study was to assess the interobserver agreement
of the Lewis score, and to validate the use of this scoring system
in clinical practice for the assessment of small-bowel Crohn’s dis-
ease.
Patients and methods
!
A retrospective, single-center, double-blind study was conducted
between May 2008 and August 2013, and included all consecu-
tive patients with isolated nonstricturing and nonpenetrating
small-bowel Crohn’s disease who underwent SBCE. Inclusion
criteria were age between 17 and 75 years, and known Crohn’s
disease of the small bowel. In the absence of a single gold stand-
ard to diagnose Crohn’s disease, patients eligible to enter the
study had an established diagnosis of Crohn’s disease based on
follow-up data with all available clinical, analytical, imaging,
endoscopic, and histological elements. Patients covering the full
spectrum of disease activity, from remission to severe disease,
were included in the study. Patients with obstructive symptoms
and/or those with evidence of ileal stenosis at ileocolonoscopy
and/or radiological features of stricturing or penetrating disease
were not eligible for SBCE andwere thus excluded from the study.
Patients taking aspirin or nonsteroidal anti-inflammatory drugs
(NSAIDs) were instructed to discontinue the medication at least
4 weeks before the SBCE examination. Patients followed a clear
liquid diet for 24 hours and fasting for 12 hours prior to SBCE
(PillCam SB2; Given Imaging Ltd., Yoqneam, Israel).
Following the examination, the SBCE videos were reviewed and
the Lewis score was calculated by one of three investigators (in-
vestigator 1 [F.D.C.], investigator 2 [J.M.], investigator 3 [M.J.M.]),
using the software application in the RAPID Reader v.6 or v.7
workstation (Given Imaging). In addition, all examinations were
independently reviewed by one experienced reader (central
reader [B.R.]), whowas blinded to the results of the other investi-
gators. The report from the central reader represented the endo-
scopic gold standard.
Using the software application to calculate the Lewis score, the
small bowel was automatically divided into equal thirds (tertiles)
based on the transit time of the capsule. In those cases where the
capsule did not reach the cecum, small-bowel tertiles were deter-
mined based on the last small-bowel image available and the re-
lative position of the capsule to the ileocecal valve, as estimated
using topographic landmarks with the localization track of the
RAPID software. For each tertile, a numeric subscore (based on
the extent and distribution of edema, and the number, size, and
distribution of ulcers) was calculated. The final score was calcu-
lated as the cumulative sum of the worst-affected tertile consid-
ering villous edema and ulcers, plus the score for stenosis (single/
multiple, ulcerated/not ulcerated, traversed/not traversed by the
capsule); the stenosis score was determined for the whole exam-
ination only and not for each tertile (●" Table1). Small-bowel in-
flammatory activity was classified into three grades: 1) normal
or clinically insignificant mucosal inflammatory change (score<
135); 2) mild disease (score≥135–<790); and 3) moderate-to-
severe disease (score≥790).
Table 1 Lewis score (adapted
from Gralnek et al. [7]).
Parameters Number Longitudinal extent1 Descriptors
Villous appearance
(worst-affected tertile)
Normal–0 Short segment–8 Single–1
Edematous–1 Long segment–12 Patchy –14
Whole tertile–20 Diffuse–17
Ulcer
(worst-affected tertile)
None–02 Short segment–5 < 1 /4–93
Single–32 Long segment–10 1 /4–1 /2–123
Few–52 Whole tertile–15 >1 /2–183
Multiple–102
Stenosis
(whole study)
None–0 Ulcerated –24 Traversed–7
Single–14 Nonulcerated–2 Not traversed–10
Multiple–20
Lewis score: Score of the worst-affected tertile [(villous parameter×extent×descriptor)+ (ulcer number×extent×size)]+stenosis score
(number×ulcerated×traversed).
1 Longitudinal extent: short segment:<10% of the tertile; long segment: 11%–50% of the tertile; whole tertile:>50% of the tertile.
2 Ulcer number: single: 1; few: 2–7; multiple:≥8.
3 Ulcer descriptor (size): proportion of the capsule picture filled by the largest ulcer.
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Statistical analysis
The mean Lewis score from each investigator was compared with
that from the central reader using the paired samples t test. The
interobserver correlation, comparing the scoring results between
the investigators and the central reader, was measured using the
Pearson correlation coefficient, for both the individual quantita-
tive scores for each tertile as well as the global small-bowel score.
Pearson correlation coefficients were considered to be low if
r≤0.35, moderate if 0.36<r<0.67, high if 0.68<r<0.89, and
very high if r>0.90. Interobserver agreements between each in-
vestigator and the central reader were determined, both for
each tertile and for the whole examination, using the intraclass
correlation coefficient (ICC), and Bland–Altman plots were
drawn for the global score. ICC was interpreted as follows: 0–
0.2 poor agreement; 0.3–0.4 fair agreement; 0.5–0.6 moderate
agreement; 0.7–0.8 strong agreement; and>0.8 almost perfect
agreement. Statistical analysis was performed using SPSS (ver-
sion 21.0; IBM Corp., Armonk, New York, USA) and MedCalc (ver-
sion 14.8.1; MedCalc Software bvba, Ostend, Belgium). P values
of<0.05 were considered to be statistically significant.
Results
!
A total of 70 consecutive patients meeting the inclusion criteria
were enrolled (mean age 33.9±11.7 years [range 17–75]; 43 fe-
males [61.4%]). The procedure was technically successful in all
patients, and the videos were available for interpretation.
The mean Lewis score was 1265±1413 (range 8–6040) and
1320±1602 (112–6204) according to the investigators and the
central reader, respectively. The comparison of mean Lewis
score in each tertile and global examination between each in-
vestigator and the central reader is summarized in●" Table2.
Overall, there was a high or very high correlation between the
investigators and the central reader both for scores obtained for
each tertile (r=0.659–0.950 for the first tertile, r=0.756–0.906
for the second tertile, and r=0.750–0.939 for the third tertile),
as well as for the global score (r=0.745–0.928) (P<0.0001)
(●" Table3). Interobserver agreement was almost perfect be-
tween the investigators and the central reader (ICC=0.788–
0.971 for the first tertile, ICC=0.824–0.943 for the second ter-
tile, ICC=0.857–0.968 for the third tertile, and ICC=0.852–
0.960 for the global Lewis score (P<0.0001) (●" Table4;●" Fig.1,
●" Fig.2, and●" Fig.3).
Overall, small-bowel inflammatory activity was classified as nor-
mal (score<135) in 2.9% vs. 2.9%, mild (score≥135–<790) in
51.4% vs. 55.7%, and moderate to severe (score≥790) in 45.8%
vs. 41.4% of patients, respectively (κ=0.7; P<0.001). The cecum
was reached in 84.3% and 87.1% of examinations according to in-
vestigators and the central reader, respectively (κ=0.884). In-
complete small-bowel examination was caused by delayed pas-
sage of the capsule at a previously unknown small-bowel steno-
sis in a minority of these patients (n=4). These capsules were
spontaneously excreted, without the need for further interven-
tion. In the remaining examinations, the procedure was incom-
plete because of battery exhaustion before the capsule entered
the cecum, as a result of delayed gastric passage or slow small-
bowel transit. Overall, the diagnosis of small-bowel stenosis was
established in 14.3% (n=10) and 18.6% (n=13) of patients, as
evaluated by the investigators and the central reader, respective-
ly (κ=0.855).
Table 2 Comparison of mean Lewis score in each tertile and global exami-
nation between each investigator and the central reader: paired samples test.
Investigator Central reader P
Investigator 1 (F.D.C.) 24 examinations
First tertile 241±307 139±261 0.047
Second tertile 378±446 218±333 0.005
Third tertile 833±700 660±702 0.100
Global score 1464±1455 1484±1744 0.916
Investigator 2 (J.M.) 23 examinations
First tertile 248±383 187±229 0.183
Second tertile 431±797 367±537 0.561
Third tertile 800±973 686±724 0.340
Global score 1071±1441 1235±1574 0.475
Investigator 3 (M.J.M.) 23 examinations
First tertile 342±480 330±431 0.702
Second tertile 217±385 221±323 0.898
Third tertile 699±7 49 576±771 0.037
Global score 1234±1533 1254±1377 0.871
Table 3 Correlations in each tertile and global examination between each
investigator and the central reader: Pearson correlation coefficient.
Correlation coefficient
(r)
P
Investigator 1 (F.D.C.) 24 examinations
First tertile 0.659 < 0.0001
Second tertile 0.833 < 0.0001
Third tertile 0.750 < 0.0001
Global score 0.842 < 0.0001
Investigator 2 (J.M.) 23 examinations
First tertile 0.875 < 0.0001
Second tertile 0.756 < 0.0001
Third tertile 0.821 < 0.0001
Global score 0.745 < 0.0001
Investigator 3 (M.J.M.) 23 examinations
First tertile 0.950 < 0.0001
Second tertile 0.906 < 0.0001
Third tertile 0.939 < 0.0001
Global score 0.928 < 0.0001
Table 4 Interobserver agreement between each investigator and the cen-
tral reader for each tertile and the global score: intraclass correlation coeffi-
cients.
ICC 95% CI P
Investigator 1 (F.D.C.) 24 examinations
First tertile 0.788 0.510–0.908 < 0.0001
Second tertile 0.888 0.742 –0.952 < 0.0001
Third tertile 0.857 0.669 –0.938 < 0.0001
Global score 0.906 0.783–0.959 < 0.0001
Investigator 2 (J.M.) 23 examinations
First tertile 0.871 0.697–0.945 < 0.0001
Second tertile 0.824 0.586 –0.926 < 0.0001
Third tertile 0.880 0.718 –0.949 < 0.0001
Global score 0.852 0.650–0.937 < 0.0001
Investigator 3 (M.J.M.) 23 examinations
First tertile 0.971 0.933–0.988 < 0.0001
Second tertile 0.943 0.866 –0.976 < 0.0001
Third tertile 0.968 0.925 –0.987 < 0.0001
Global score 0.960 0.905–0.983 < 0.0001
ICC, intraclass correlation coefficient; CI, confidence interval.
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Discussion
!
This study demonstrated that the Lewis score is a reproducible
test to evaluate established Crohn’s disease. There was strong in-
terobserver agreement for the determination of the Lewis score,
validating this score for the reporting of small-bowel inflamma-
tory activity. Thus, the Lewis score might be used in clinical prac-
tice for diagnosing, staging, follow-up, and therapeutic assess-
ment of patients with small-bowel Crohn’s disease.
Globally, mean scores in each tertile and the global Lewis score
were similar between the investigators and the central reader.
There was a high or very high correlation for scoring results
with almost perfect interobserver agreement. Interestingly, the
analysis of Bland–Altman plots indicates that interobserver
agreementmay be lower for the highest scores, considering abso-
lute numeric values, although it does not seem to influence the
assessment of global disease severity according to the classifica-
tion of the Lewis score, which stratifies small-bowel inflamma-
tory activity into three grades (<135, normal or clinically insig-
nificant mucosal inflammatory change;≥135–<790, mild dis-
ease; and≥790, moderate-to-severe disease). Indeed, overall,
the differences between investigators, according to this classifi-
cation, did not affect the global assessment of disease severity,
which is clinically meaningful: to date, no study has evaluated
whether there are different clinical or prognostic implications
associated with scores of different magnitude above the cutoff of
790, and therefore there is uncertainty over whether these differ-
ences may be clinically relevant.
The availability of an objective scoring system to assess inflam-
matory activity and disease extent enables the use of a common
language andmethodology for the interpretation and description
of lesions consistent with Crohn’s disease, and it may contribute
to the establishment of cutoff levels indicative of the grade of se-
verity with an adequate interobserver agreement. The adoption
of reproducible scoring systems has been encouraged by recently
published European Crohn’s and Colitis Organisation guidelines
[1]. The Lewis score [7,10] is a cumulative scoring system based
on the presence and distribution of villous edema, ulceration,
and stenosis, which were the endoscopic findings with the high-
est interobserver agreement according to the original authors of
the score (κ=0.48, κ=0.66, and κ=0.58, respectively). Due to low
interobserver agreement and/or perceived lack of clinical signifi-
cance, other mucosal findings such as minor mucosal breaks, er-
ythema, villous atrophy, or nodularity [10] were not included for
the calculation of the score. The easy-to-use software application
for the automatic calculation of the Lewis score is a clear advan-
tage of the instrument compared with CECDAI, which currently
has no software tool for its automatic calculation. Moreover, no
threshold levels of inflammatory activity have been defined for
CECDAI, although it has been suggested that CECDAI levels of 3.8
and 5.8 may correspond to the Lewis score thresholds of 135 and
790, respectively [11].
A wide range of different clinical scenarios require the objective
assessment of small-bowel inflammatory activity in clinical prac-
tice. In patients with suspected Crohn’s disease after nondiagnos-
tic ileocolonoscopy, it is possible to confidently exclude the diag-
nosis if no significant small-bowel mucosal changes are identi-
fied by the capsule, because the capsule has high sensitivity
even for subtle mucosal changes [6,12]. Conversely, SBCE may
be a key diagnostic tool in this setting if it reveals small-bowel le-
sions consistent with Crohn’s disease in a proper clinical context.
In this study, the gold standard for the diagnosis of Crohn’s dis-
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Fig.1 Bland–Altman plot 1: interobserver agreement for global Lewis
score between investigator 1 and the central reader.
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Fig.2 Bland–Altman plot 2: interobserver agreement for global Lewis
score between investigator 2 and the central reader.
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Fig.3 Bland–Altman plot 3: interobserver agreement for global Lewis
score between investigator 3 and the central reader.
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ease did not rely solely on SBCE findings, but resulted from a
combination of all available follow-up data, as described in the
Methods section. Indeed, the diagnosis of Crohn’s disease is con-
firmed histologically in only a minority of patients in routine
clinical practice [13], either due to the inaccessibility of lesions
or because biopsies are also often unspecific. Thus, usually the di-
agnosis is based on a conjunction of clinical, biochemical, endo-
scopic, and imaging elements. In our center, we do not routinely
perform flexible enteroscopy to obtain biopsies of small-bowel
lesions that are consistent with Crohn’s disease as detected by
SBCE if the patient has a high pre-test probability of Crohn’s dis-
ease. In a recent study from our center in patients with suspected
Crohn’s disease, the diagnosis was confirmed during follow-up in
82.6% of those with significant inflammatory activity on SBCE
(Lewis score≥135), but in only 12.1% of those with a score lower
than 135 [14].
However, although the Lewis score can be used to quantitatively
describe the type, distribution, and severity of mucosal lesions,
endoscopic findings are nonspecific [4], and scoring systems
grade inflammatory activity independently of its etiology. In-
deed, lesions resembling Crohn’s disease on SBCE are indistin-
guishable from NSAID-induced enteropathy or other causes of
small-bowel mucosal damage such as infections, Behçet disease,
ischemia, or vasculitis [1]. To date, no study has addressed
whether the interobserver variability could be influenced by the
type of indication for SBCE, namely whether the inflammatory
activity would be graded differently in patients with suspected
Crohn’s disease or an alternative diagnosis compared with those
with a previously known established diagnosis of Crohn’s dis-
ease. Although this seems unlikely when a standard, objective,
and validated methodology for the assessment of inflammatory
activity is followed, this is an interesting topic of investigation
that could merit further investigation.
The role of SBCE in patients with previously established Crohn’s
disease is currently evolving. It may be used to evaluate disease
extent and activity in the small bowel, as proximal and/or exten-
ded inflammatory activity has been shown to be associated with
poor prognosis and adverse outcomes [15,16], and it may have
an impact on therapeutic management towards an earlier intro-
duction of immunomodulators and/or biologic therapy [17–19].
In a recently published retrospective study from our center, treat-
ment with thiopurines and/or biologics was started more often
in patients with proximal small-bowel lesions [13/33 (39%) vs.
1 /17 (6%); P=0.011, relative risk 6.5], particularly when severe
as determined by the Lewis score (6%, 36%, and 45% of patients
with nonsignificant, mild, and moderate-to-severe inflamma-
tion, respectively) [18]. SBCE may also be considered in the post-
operative setting [20,21], or to investigate patients with atypical
symptoms, unexplained anemia, or obscure gastrointestinal
bleeding [1]. SBCE has also been evaluated as a noninvasive diag-
nostic tool for the assessment of mucosal healing after therapy,
an important end point of treatment efficacy, which has been
associated with sustained clinical remission and improved out-
comes [1,22,23]. For all these indications, the objective quantifi-
cation of small-bowel inflammatory activity by using a validated
scoring methodology seems pivotal.
In this study, a strong correlationwas demonstrated between the
investigators and the central reader, both for scores obtained for
each tertile as well as for the global Lewis score. Although the
study was retrospective, it was based on prospectively collected
database. A strong interobserver agreement was demonstrated
for the Lewis score, validating this score for the reporting of
small-bowel inflammation in a practical clinical setting. Previous
studies have evaluated the correlation of endoscopic scoring sys-
temswith clinical objectivemeasures, such as the Crohn’s disease
activity index or the inflammatory bowel disease questionnaire.
Although this could be a topic for future investigations, several
previous trials have failed to demonstrate an association between
endoscopic scores and clinical scores in Crohn’s disease [9,24,
25]. This may be due to the fact that clinical activity is objectively
difficult to assess, and also because symptoms such as abdominal
pain or diarrhea that may resemble Crohn’s disease flare-ups
may be multifactorial and unrelated to the existence of promi-
nent gastrointestinal inflammatory lesions [9,24,25].
To summarize, the Lewis score has been shown to be a practical
and reproducible instrument that might be used in the diagnosis,
staging, follow-up, and therapeutic assessment of patients with
isolated small-bowel Crohn’s disease.
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